Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wassilis S C Bruins

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Frontiers in Immunology|July 9, 2020
Targeted Therapy With Immunoconjugates for Multiple MyelomaWassilis S C Bruins, Sonja Zweegman, Tuna Mutis, et al.
JCO Precision Oncology|September 14, 2020
Hypermethylated <i>RASSF1A</i> as Circulating Tumor DNA Marker for Disease Monitoring in NeuroblastomaLieke M J van Zogchel, Esther M van Wezel, Jalenka van Wijk, et al.
Journal for Immunotherapy of Cancer|July 26, 2024
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myelomaCharlotte L B M Korst, Chloe O'Neill, Wassilis S C Bruins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2024
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple MyelomaChristie P M Verkleij, Chloe A O'Neill, Marloes E C Broekmans, et al.
Hemasphere|November 15, 2024
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myelomaWassilis S C Bruins, Rosa Rentenaar, John Newcomb, et al.
Blood|August 19, 2025
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapyWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere|April 20, 2026
Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myelomaRamin Raoof, Giada Dal Collo, Helga Simon-Molas, et al.
Blood Advances|January 8, 2024
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOSA Vera de Jonge, Carolien Duetz, Wassilis S C Bruins, et al.
Hemasphere|October 7, 2025
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levelsWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere|May 8, 2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple MyelomaChristie P M Verkleij, Kristine A Frerichs, Marloes E C Broekmans, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Frontiers in Immunology|July 9, 2020
Targeted Therapy With Immunoconjugates for Multiple MyelomaWassilis S C Bruins, Sonja Zweegman, Tuna Mutis, et al.
JCO Precision Oncology|September 14, 2020
Hypermethylated <i>RASSF1A</i> as Circulating Tumor DNA Marker for Disease Monitoring in NeuroblastomaLieke M J van Zogchel, Esther M van Wezel, Jalenka van Wijk, et al.
Journal for Immunotherapy of Cancer|July 26, 2024
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myelomaCharlotte L B M Korst, Chloe O'Neill, Wassilis S C Bruins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2024
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple MyelomaChristie P M Verkleij, Chloe A O'Neill, Marloes E C Broekmans, et al.
Hemasphere|November 15, 2024
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myelomaWassilis S C Bruins, Rosa Rentenaar, John Newcomb, et al.
Blood|August 19, 2025
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapyWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere|April 20, 2026
Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myelomaRamin Raoof, Giada Dal Collo, Helga Simon-Molas, et al.
Blood Advances|January 8, 2024
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOSA Vera de Jonge, Carolien Duetz, Wassilis S C Bruins, et al.
Hemasphere|October 7, 2025
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levelsWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere|May 8, 2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple MyelomaChristie P M Verkleij, Kristine A Frerichs, Marloes E C Broekmans, et al.
Pageof 2